Navidea Biopharma (NAVB) Tops Q3 EPS by 3c

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $96 thousand, versus $268 thousand reported last year.

Navidea ended the third quarter of 2021 with $7.2 million in cash and cash equivalents.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS cuts KOSPI target by nearly 10% to reflect higher rates
• Lumentum shares rise on analyst upgrades, AI demand outlook